Vivos Therapeutics (VVOS) Competitors $2.74 -0.11 (-3.70%) As of 11:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VVOS vs. ECOR, APT, SPAI, TMDIF, DXR, APYX, BDMD, OM, TELA, and MODDShould you be buying Vivos Therapeutics stock or one of its competitors? The main competitors of Vivos Therapeutics include electroCore (ECOR), Alpha Pro Tech (APT), Safe Pro Group Inc. Common Stock (SPAI), Titan Medical (TMDIF), Daxor (DXR), Apyx Medical (APYX), Baird Medical Investment (BDMD), Outset Medical (OM), TELA Bio (TELA), and Modular Medical (MODD). These companies are all part of the "medical equipment" industry. Vivos Therapeutics vs. electroCore Alpha Pro Tech Safe Pro Group Inc. Common Stock Titan Medical Daxor Apyx Medical Baird Medical Investment Outset Medical TELA Bio Modular Medical electroCore (NASDAQ:ECOR) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, community ranking, profitability, valuation and risk. Do analysts rate ECOR or VVOS? electroCore currently has a consensus price target of $25.50, indicating a potential upside of 251.92%. Vivos Therapeutics has a consensus price target of $6.10, indicating a potential upside of 123.03%. Given electroCore's higher possible upside, equities analysts plainly believe electroCore is more favorable than Vivos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score electroCore 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Vivos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings and valuation, ECOR or VVOS? Vivos Therapeutics has lower revenue, but higher earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioelectroCore$25.18M2.07-$18.83M-$1.62-4.47Vivos Therapeutics$15.03M1.07-$13.58M-$2.91-0.94 Do insiders & institutionals believe in ECOR or VVOS? 26.7% of electroCore shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 19.7% of electroCore shares are owned by insiders. Comparatively, 3.0% of Vivos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is ECOR or VVOS more profitable? electroCore has a net margin of -54.40% compared to Vivos Therapeutics' net margin of -86.19%. electroCore's return on equity of -154.45% beat Vivos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets electroCore-54.40% -154.45% -69.16% Vivos Therapeutics -86.19%-335.04%-93.58% Which has more risk & volatility, ECOR or VVOS? electroCore has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.31, indicating that its share price is 631% more volatile than the S&P 500. Does the MarketBeat Community believe in ECOR or VVOS? electroCore received 150 more outperform votes than Vivos Therapeutics when rated by MarketBeat users. Likewise, 62.55% of users gave electroCore an outperform vote while only 60.71% of users gave Vivos Therapeutics an outperform vote. CompanyUnderperformOutperformelectroCoreOutperform Votes16762.55% Underperform Votes10037.45% Vivos TherapeuticsOutperform Votes1760.71% Underperform Votes1139.29% Does the media favor ECOR or VVOS? In the previous week, electroCore had 5 more articles in the media than Vivos Therapeutics. MarketBeat recorded 7 mentions for electroCore and 2 mentions for Vivos Therapeutics. Vivos Therapeutics' average media sentiment score of 1.44 beat electroCore's score of 0.91 indicating that Vivos Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment electroCore Positive Vivos Therapeutics Positive SummaryelectroCore beats Vivos Therapeutics on 12 of the 16 factors compared between the two stocks. Get Vivos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VVOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VVOS vs. The Competition Export to ExcelMetricVivos TherapeuticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.11M$4.37B$5.53B$7.99BDividend YieldN/A39.94%5.11%4.23%P/E Ratio-0.4830.8122.6518.64Price / Sales1.0755.50401.98103.80Price / CashN/A51.0838.1834.62Price / Book12.436.096.754.30Net Income-$13.58M$68.71M$3.22B$248.44M7 Day Performance0.92%-0.18%1.66%1.81%1 Month Performance3.99%-2.33%4.17%4.40%1 Year Performance9.40%23.51%16.17%5.97% Vivos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VVOSVivos Therapeutics2.7893 of 5 stars$2.74-3.7%$6.10+123.0%+12.3%$16.11M$15.03M-0.48160Short Interest ↓Positive NewsGap DownECORelectroCore2.4001 of 5 stars$6.51+8.1%$25.50+291.7%+20.3%$46.83M$25.18M-3.5650Upcoming EarningsNews CoverageHigh Trading VolumeAPTAlpha Pro TechN/A$4.26-0.7%N/A-27.2%$46.32M$57.84M11.51120Analyst ForecastSPAISafe Pro Group Inc. Common StockN/A$2.70+9.8%N/AN/A$40.96M$2.17M0.0011Gap UpTMDIFTitan MedicalN/A$0.36+7.8%N/A+554.9%$40.77M$17.63M-0.2950Gap DownDXRDaxor3.998 of 5 stars$7.98+7.7%$25.00+213.3%-23.8%$38.60M$2.13M0.0037Gap UpAPYXApyx Medical1.3954 of 5 stars$0.98+0.5%N/A-27.3%$37.04M$48.10M-1.18270Upcoming EarningsShort Interest ↑News CoverageGap DownBDMDBaird Medical InvestmentN/A$5.55-0.7%N/AN/A$36.54M$33.05M0.00N/AOMOutset Medical1.048 of 5 stars$9.98-9.4%$35.00+250.7%-72.0%$35.88M$113.69M-4.02520Upcoming EarningsTELATELA Bio2.9792 of 5 stars$0.89-6.9%$7.25+714.6%-78.5%$35.06M$69.30M-0.53120Upcoming EarningsShort Interest ↓MODDModular Medical1.9626 of 5 stars$0.85-4.2%N/A-31.6%$34.61MN/A-1.6120Short Interest ↓Negative News Related Companies and Tools Related Companies electroCore Competitors Alpha Pro Tech Competitors Safe Pro Group Inc. Common Stock Competitors Titan Medical Competitors Daxor Competitors Apyx Medical Competitors Baird Medical Investment Competitors Outset Medical Competitors TELA Bio Competitors Modular Medical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VVOS) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vivos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
